Neurocrine Biosciences | NBIX - Current Liabilities


Neurocrine Biosciences reported $831.7M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
AbbVie USD 42.1B 1.19B Mar/2026
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
Agios Pharmaceuticals USD 58.84M 23.36M Mar/2026
ALKERMES USD 599.5M 56.06M Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
Amgen USD 24.96B 534M Mar/2026
Biogen USD 3B 350.5M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Cytokinetics USD 199.18M 3.27M Mar/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Exelixis USD 370.98M 34.67M Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
Incyte USD 1.49B 25.52M Mar/2026
Ionis Pharmaceuticals USD 717M 66M Mar/2026
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Neurocrine Biosciences USD 831.7M 88.3M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Prothena USD 32.52M 8.33M Mar/2026
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Repligen USD 126.21M 9.62M Mar/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Teva Pharmaceutical Industries USD 13.53B 76M Mar/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026
Xoma USD 28.3M 6.81M Sep/2025